Kopion Asset Management LLC Has $5.92 Million Holdings in Certara, Inc. (NASDAQ:CERT)

Kopion Asset Management LLC boosted its stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 46.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 555,643 shares of the company's stock after purchasing an additional 175,005 shares during the period. Certara comprises approximately 4.2% of Kopion Asset Management LLC's holdings, making the stock its 14th largest position. Kopion Asset Management LLC owned approximately 0.35% of Certara worth $5,918,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in CERT. GAMMA Investing LLC increased its position in Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company's stock worth $90,000 after purchasing an additional 6,868 shares during the last quarter. 272 Capital LP bought a new stake in shares of Certara in the 3rd quarter valued at approximately $586,000. Barclays PLC increased its holdings in Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company's stock worth $825,000 after buying an additional 46,880 shares during the last quarter. Jane Street Group LLC raised its position in Certara by 2.6% during the third quarter. Jane Street Group LLC now owns 147,393 shares of the company's stock valued at $1,726,000 after acquiring an additional 3,732 shares in the last quarter. Finally, State Street Corp lifted its stake in Certara by 3.4% in the third quarter. State Street Corp now owns 3,679,699 shares of the company's stock valued at $43,089,000 after acquiring an additional 122,411 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Stock Performance

NASDAQ:CERT traded up $1.22 during midday trading on Wednesday, reaching $11.96. The stock had a trading volume of 1,770,361 shares, compared to its average volume of 981,351. The stock has a market capitalization of $1.93 billion, a P/E ratio of -59.80, a PEG ratio of 5.86 and a beta of 1.52. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The firm's fifty day simple moving average is $10.86 and its 200-day simple moving average is $11.95.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to analysts' expectations of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business's quarterly revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.06 earnings per share. On average, equities research analysts forecast that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on CERT shares. Barclays dropped their price target on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 7th. UBS Group raised shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a research report on Friday, September 27th. Finally, Robert W. Baird reduced their price target on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a research report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, Certara currently has an average rating of "Hold" and a consensus target price of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.